1 – 9 of 9
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine
(
- Contribution to journal › Article
-
Mark
Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Pancreatic Ductal Adenocarcinoma : Current and Evolving Therapies
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Integrin β1, osmosensing, and chemoresistance in mouse ehrlich carcinoma cells
(
- Contribution to journal › Article
- 2012
-
Mark
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
(
- Contribution to journal › Article
- 2009
-
Mark
Bacterial Deoxyribonucleoside Kinases Are Poor Suicide Genes in Mammalian Cells
(
- Contribution to journal › Article
-
Mark
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
(
- Contribution to journal › Article
- 2007
-
Mark
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer
(
- Contribution to journal › Article